18.2 Subpopulations of blood lymphocytes in long-surviving renal transplant patients, comparison with healthy volunteers
Mr. Prateek Rakesh, Australia
18.3 Conversion to Belatacept in Kidney Transplant Recipients
Mr. Peter J FIoramonti, United States
18.4 Which pathological factors affect kidney allograft outcome in chronic active antibody-mediated rejection?
Dr. Kazunobu Shinoda, Japan
18.5 Frequency and stability of subpopulations of CD4+CD25+Foxp3+CD127lo T regulatory cells in healthy adult volunteers
Ranje Al-Atiyah, Australia
18.6 New approach to therapeutic drug monitoring of mycophenolic acid (MPA) and mycophenolic acid glucuronide (MPAG) based on pharmacokinetics for solid organ transplant patients using LC-MS/MS